At Freenome, we pride ourselves on the collaboration of our diverse team of clinicians, machine learning scientists, biologists, and business specialists.
Freenome, a privately held biotech company, today announced the launch of the Sanderson Study, the company’s latest study of its multiomics platform, in combination with real-world data to detect multiple cancers.
Sep 8, 2022 | repertoiremag.comFreenome is developing a CRC screening test using a routine blood draw to detect cancer in its earliest stages.
Mar 14, 2022 | freenome.comFreenome recently launched the Vallania Study, a clinical study to evaluate and extend the platform for the early detection of multiple cancers.
Jan 1, 2022 | freenome.comFreenome, a privately held biotech company, announced its co-authorship of a study with Merck KGaA, Darmstadt Germany, a leading science and technology company.
Jan 1, 2022 | yahoo.comEarlier this year, Freenome launched its first prospective clinical study for multi-cancer early detection with several partners from PREEMPT CRC.
Jan 1, 2022 | pharmtechfocus.comCharles joins Freenome from Western Digital where he was senior vice president and chief financial officer for the Flash division.
Jan 1, 2022 | prnewswire.comFreenome Inc. partnered with Haircuts with Heart to provide hair & nail services (which was by far the most popular).
Jan 1, 2020 | freenome.com“Dr. Tzou joins Freenome at an exciting point in its growth and Freenome Inc. is pleased to welcome him to the team,” said Girish Putcha, M.D., Ph.D., Chief Medical Officer at Freenome.
Jan 1, 2017 | businesswire.com